ClinicalTrials.gg
RecruitingNCT07602777Updated Oct 1, 2026

A Study Evaluating the Efficacy and Safety of Risvutatug Rezetecan in Participants With Advanced Sarcomas (EMBOLD Sarcoma-202)

A Phase 1/2 interventional study of Ris-Rez and G-CSF in Sarcoma, sponsored by GlaxoSmithKline. Recruiting at 13 sites in 6 countries. Per ClinicalTrials.gov, last updated 2026-10-01.

Sponsored by GlaxoSmithKline · Phase 1/2, Interventional, and Treatment

From the registry’s dates

  • Started Jun 2026; still recruiting 4 months later.
Updated Oct 1, 2026First sites in Israel, United Kingdom and United StatesPrimary completion moved+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
64
Allocation
Randomized
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 175 studies in Sarcoma with a site in France — 49 open to participants now, 64 under way, 8 of them phase 3. Sarcoma · France.

Planned enrollment
107th of 152
64 · median 115
Started
2026
with 5 others
Phase 1/2
25 of 175
7 open now
Primary completion
2027-11
later than 32 of 63 live
Registered
172nd of 175
by date

Among the 175 studies in Sarcoma with a site in France, this one is the 107th largest by planned enrollment of the 152 interventional ones that give a count, is one of 6 that started in 2026, is one of 25 in phase 1/2, reaches primary completion later than 32 of the 63 other live ones, and was the 172nd registered.

Sarcoma

1,609 studies on the registry are indexed under Sarcoma; 367 are open to participants now.

Browse Sarcoma studies →

Open to participants now

49 of the 175 studies in Sarcoma with a site in France are open now. Recruiting first, the newest first:

43 more — sign in →

All 49 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 302 Sarcoma studies recruiting now, 192 (64%) set no upper age limit and 83 (27%) stop at 75 or younger; 93 take children under 18; 12 take healthy volunteers.

This study: all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 175 studies in Sarcoma with a site in France, or all of them as a file.
02

Study summary

The main goal of this study is to test a new medicine, Risvutatug Rezetecan also called Ris-Rez. We want to see if this medicine can help people with certain types of cancer, whether its safe to use, how well people tolerate it, and how their bodies handle the drug (how its absorbed and broken down). This research is for adolescents and adults who have either: Osteosarcoma, which is a type of bone cancer, or Soft Tissue Sarcoma, which is a type of cancer that starts in soft body tissues (like muscle, fat, or nerves). In both cancer types the cancer must have already been treated, but has come back or spread, and cant be removed by surgery

03

Conditions studied

  • Sarcoma

Browse trials for

Keywords

  • EMBOLD Sarcoma-202
  • Risvutatug Rezetecan
  • Ris-Rez
  • Sarcoma
04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

- Participants are eligible to be included in the study only if all of the following criteria apply

  • Participants must be ≥ 12 years of age.
  • Has confirmed unresectable advanced or R/R OSA (Cohort 1) or unresectable advanced or metastatic STS (Cohort 2) that has progressed to at least one .
  • Has documented disease progression on the last line of systemic treatment as confirmed by radiological imaging
  • Has an performance status of 0 or 1, or Lansky PS/ PS ≥ 70% for adolescent participants, with no deterioration in the 2 weeks prior to first dose/randomization.
  • Has adequate organ function.
  • All participants, or their legal guardians, must provide signed and agree to follow the study protocol before starting any study activities

Exclusion criteria

Exclusion Criteria:

- Participants are excluded from the study if any of the following key exclusion criteria apply:

  • Has received any prior therapy with an Antibody-drug-conjugates (ADC) with a TOPO1-inhibitor payload.
  • Has known sensitivity to study intervention components or or other allergy that, in the opinion of the investigator or medical monitor, contraindicates participation in the study.
  • Has severe, uncontrolled or active cardiovascular disorders.
  • Known active infectious diseases requiring systemic treatment or known (HIV).
  • Has symptomatic or untreated progression exclusively due to brain metastasis during or after the last treatment prior to screening, evidence of /meningeal/brainstem or evidence of spinal cord metastases.
  • Has received treatment with an agent within 4 weeks of the first dose of study intervention.
  • Is pregnant or breastfeeding.
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
64 participants (estimated)

Study arms

  • Experimental
    Cohort 1A (Ris-Rez)

    Biological: Ris-Rez

  • Experimental
    Cohort 1B [Ris-Rez + Granulocyte-Colony Stimulating Factor (G-CSF)]

    Biological: Ris-Rez · Biological: G-CSF

  • Experimental
    Cohort 2 (Ris-Rez)

    Biological: Ris-Rez

Interventions

  • BiologicalRis-Rez

    Ris-Rez will be administered

  • BiologicalG-CSF

    G-CSF will be administered

06

What researchers measure

Primary outcomes

  1. Cohort 1: Progression free survival rate at Week18 (PFS18)

    PFS is defined as the time from the date of randomization until the date of documented disease progression or death due to any cause, whichever occurs first, as assessed by the investigator according to Response Evaluation Criteria in Solid Tumors, version 1.1 (RECIST 1.1)

    Time frame: At Week 18

  2. Cohort 1 & 2: Confirmed Objective Response Rate (ORR)

    Confirmed ORR is defined as the proportion of participants who have achieved a confirmed Complete Response (CR) or Partial Response PR as assessed by investigator, according to RECIST 1.1

    Time frame: Up to approximately 98 weeks

Secondary outcomes

  1. Cohort 1 & 2: Number of participants with Adverse events (AEs) and serious AEs (SAEs) by severity

    Time frame: Up to approximately 179 weeks

  2. Cohort 1 & 2: Number of participants with AEs/SAEs leading to dose modifications or study intervention discontinuation or death

    Time frame: Up to approximately 179 weeks

  3. Cohort 1 & 2: Number of participants with a change from baseline in vital signs

    Number of participants will be assessed

    Time frame: Baseline (Day-1) and up to approximately 179 weeks

  4. Cohort 1 & 2: Number of participants with a change from baseline in body weight

    Number of participants will be assessed

    Time frame: Baseline (Day-1) and up to approximately 179 weeks

  5. Cohort 1 & 2: Number of participants with a change from baseline in laboratory parameters (haematology and clinical chemistry)

    Number of participants will be assessed

    Time frame: Baseline (Day-1) and up to approximately 179 weeks

  6. Number of participants with a change from baseline in cardiac function [Electrocardiogram (ECG)]

    Number of participants will be assessed

    Time frame: Baseline (Day-1) and up to approximately 179 weeks

  7. Number of participants with a change from baseline in Eastern Cooperative Oncology Group (ECOG) performance status

    Number of participants will be assessed

    Time frame: Baseline (Day-1) and up to approximately 179 weeks

  8. Cohort 2: PFS rate at Week 18 (PFS18)

    PFS is defined as the time from the date of randomization until the date of documented disease progression or death due to any cause, whichever occurs first, as assessed by the investigator according to RECIST 1.1

    Time frame: At Week 18

  9. Cohort 1 & 2: Duration of response (DoR)

    DoR is defined as the time from the date of the first documented objective response (CR/PR) that is subsequently confirmed, until the date of the first documented PD or death, whichever is earlier, as assessed by investigator according to RECIST 1.1

    Time frame: Up to approximately 179 weeks

  10. Cohort 1 & 2: PFS rate at Week 30 (PFS30)

    PFS is defined as the time from the date of randomization until the date of documented disease progression or death due to any cause, whichever occurs first, as assessed by the investigator according to RECIST 1.1

    Time frame: At Week 30

  11. Cohort 1 & 2: PFS

    PFS is defined as the time from the date of randomization until the date of documented disease progression or death due to any cause, whichever occurs first, as assessed by the investigator according to RECIST 1.1

    Time frame: Up to approximately 179 weeks

  12. Cohort 1 & 2: Unconfirmed ORR

    Unconfirmed ORR is defined as the proportion of participants who have achieved a response of CR or PR (without confirmation) as assessed by the investigator according to RECIST 1.1.

    Time frame: Up to approximately 179 weeks

  13. Cohort 1 & 2: Observed pharmacokinetic (PK) concentration of Ris-Rez (conjugated antibody) and payload

    Time frame: Up to approximately 179 weeks

  14. Cohort 1 & 2: Proportion of participants with positive and total Antidrug antibody (ADA) and Neutralizing Antibody (NAb) against Ris-Rez

    Time frame: Up to approximately 179 weeks

  15. Cohort 1 & 2: Titers of ADA against Ris-Rez

    Time frame: Up to approximately 179 weeks

  16. Cohort 1 & 2: Participant-reported experience on study treatment

    Number of participants who reported their experience with study treatment using validated questionnaires will be measured

    Time frame: Up to approximately 179 weeks

07

Study locations

13 of 13 sites recruiting
  • GSK Investigational Site
    West Valley City, Utah 84119-3602, United States
    Recruiting
  • GSK Investigational Site
    Toronto, Ontario M5G 2M9, Canada
    Recruiting
  • GSK Investigational Site
    Montreal, Quebec H4A 3J1, Canada
    Recruiting
  • GSK Investigational Site
    Bordeaux, 33076, France
    Recruiting
  • GSK Investigational Site
    Lyon, 69373, France
    Recruiting
  • GSK Investigational Site
    Villejuif, 94805, France
    Recruiting
  • GSK Investigational Site
    Jerusalem, 91120, Israel
    Recruiting
  • GSK Investigational Site
    Tel Aviv, 64239, Israel
    Recruiting
  • GSK Investigational Site
    Fukuoka, 812-8582, Japan
    Recruiting
  • GSK Investigational Site
    Hokkaido, 003-0804, Japan
    Recruiting
  • GSK Investigational Site
    Tokyo, 104-0045, Japan
    Recruiting
  • GSK Investigational Site
    Manchester, Greater Manchester M20 4BX, United Kingdom
    Recruiting
  • GSK Investigational Site
    London, NW1 2BU, United Kingdom
    Recruiting
08

References and documents

Individual participant data

Plan to share: Yes — Study Sponsor will assess requests from qualified researchers for anonymized individual patient-level data and related study documents. Data sharing is subject to certain criteria, conditions, and exceptions. For further information, refer to https://www.gsk-studyregister.com/gsk-patient-level-data-sharing-july2025.pdf

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Time frame: Anonymized IPD will be made available within 6 months of publication of primary, key secondary and safety results for studies in product with approved indication(s) or asset(s) with development terminated across all indications.

Access criteria: Anonymized IPD is shared with researchers whose proposals are approved by an Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months, but an extension may be granted, when justified, for up to 6 months.

Data sharing details ↗ · www.gsk-studyregister.com

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2026 (actual). Primary completion is estimated for Nov 2027, 16 months after the start.

Of 44 industry-sponsored phase 1/2 interventional studies under Sarcoma, half reached primary completion within 59 months of starting (the median), counting those still running; a quarter within 43 and three quarters within 89. This study's planned 16 months is below that.

Counting every sponsor, half of 101 studies reached it within 62 months; a quarter within 45 and three quarters within 106.

How these figures are worked out, and which studies are left out of them.

Registered
May 11, 2026
First posted
May 22, 2026
StartActual
Jun 22, 2026
Primary completionEst.
Nov 5, 2027
CompletionEst.
Nov 23, 2029
Last update
Oct 1, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
7 sites added — first sites in Israel, United Kingdom and United States
Show 7 added (2 Israel, 2 Japan, 2 United Kingdom, 1 United States)
  • GSK Investigational Site · West Valley City, United States
  • GSK Investigational Site · Jerusalem, Israel
  • GSK Investigational Site · Tel Aviv, Israel
  • GSK Investigational Site · Fukuoka, Japan
  • GSK Investigational Site · Tokyo, Japan
  • GSK Investigational Site · Manchester, United Kingdom
  • GSK Investigational Site · London, United Kingdom
Oct 1, 2026
Primary completion
Nov 18, 2027→Nov 5, 2027
Oct 1, 2026
Enrollment
113→64
Oct 1, 2026
Site contacts
Changed at 1 site. See the sites
Show the site
  • GSK Investigational Site · Toronto, CanadaContact person changed (no phone or email listed)
Oct 1, 2026
Show all 1 update
  1. Oct 1, 2026
    7 sites added — first sites in Israel, United Kingdom and United States
    Show 7 added (2 Israel, 2 Japan, 2 United Kingdom, 1 United States)
    • GSK Investigational Site · West Valley City, United States
    • GSK Investigational Site · Jerusalem, Israel
    • GSK Investigational Site · Tel Aviv, Israel
    • GSK Investigational Site · Fukuoka, Japan
    • GSK Investigational Site · Tokyo, Japan
    • GSK Investigational Site · Manchester, United Kingdom
    • GSK Investigational Site · London, United Kingdom
    Primary completion Nov 18, 2027→Nov 5, 2027
    Enrollment 113→64
    Site contacts Changed at 1 site. See the sites
    Show the site
    • GSK Investigational Site · Toronto, CanadaContact person changed (no phone or email listed)
    + 2 other changes: identifiers and verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07602777
Lead sponsor
GlaxoSmithKline
Responsible party
Sponsor
First posted
May 22, 2026
Start date
Jun 22, 2026
Primary completion
Nov 5, 2027 (estimated)
Completion
Nov 23, 2029 (estimated)
Last update
Oct 1, 2026

Study contacts

US GSK Clinical Trials Call Center
Contact
GSKClinicalSupportHD@gsk.com
877-379-3718
EU GSK Clinical Trials Call Center
Contact
GSKClinicalSupportHD@gsk.com
+44 (0) 20 89904466

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Risvutatug rezetecan · Granulocyte Colony-Stimulating Factor

Start the discussion